Target expression details
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T73097 | ||||
| Target Name | GM-CSF receptor alpha | ||||
| Synonyms | CD116 antigen; CDw116; GM-CSF-R-alpha; GM-CSFR; GMR; CSF2RA | ||||
| Target Type | Successful | ||||
| Gene Name | CSF2RA | ||||
| Biochemical Class | Type I cytokine receptor | ||||
| UniProt ID | CSF2R_HUMAN | ||||
| Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
| Disease | Acute myelocytic leukemia | ||||
| Example drug | Leukemia cancer vaccine | Phase 2 | [1], [2] | ||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.49 Z-score: -0.88 P-value: 1.10E-05 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Glioma | ||||
| Example drug | AFTVac | Phase 2 | [3], [2] | ||
| Tissue | Brainstem tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.13 Z-score: -0.28 P-value: 7.80E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Glioma | ||||
| Example drug | AFTVac | Phase 2 | [3], [2] | ||
| Tissue | White matter | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.44 Z-score: 0.38 P-value: 1.96E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Myeloma | ||||
| Example drug | Myeloma cancer vaccine | Phase 2 | [1], [2] | ||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.14 Z-score: 1.25 P-value: 3.76E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rectal cancer | ||||
| Example drug | Colorectal cancer vaccine | Phase 2 | [4], [2] | ||
| Tissue | Rectal colon tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.43 Z-score: -2.15 P-value: 4.48E-03 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: -0.25 Z-score: -1.13 P-value: 1.01E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | Mavrilimumab | Phase 2 | [5], [6], [2] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.16 Z-score: 0.53 P-value: 8.42E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Multiple sclerosis | ||||
| Example drug | MOR-103 | Phase 1/2 | [7], [2] | ||
| Tissue | Spinal cord | ||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 0.06 Z-score: 0.24 P-value: 1.58E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
|
|||||
| Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
|
|||||
| Reference | |||||
| REF 1 | ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health. | ||||
| REF 2 | NCBI GEO: archive for functional genomics data sets--update. | ||||
| REF 3 | Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9. | ||||
| REF 4 | Clinical pipeline report, company report or official report of Aduro BioTech. | ||||
| REF 5 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7785). | ||||
| REF 6 | Clinical pipeline report, company report or official report of MedImmune (2011). | ||||
| REF 7 | ClinicalTrials.gov (NCT01023256) Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.